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Madrid, 11) University Hospital Virgen Macarena, Sevilla and 12) University Hospital 12 de Octubre, Madrid, SpainAbstractPreventing inﬂuenza infection early after transplantation is essential, given the disease’s high mortality. A multicentre prospective cohort study
in adult solid organ transplant recipients (SOTR) receiving the inﬂuenza vaccine during four consecutive inﬂuenza seasons (2009–2013) was
performed to assess the immunogenicity and safety of inﬂuenza vaccination in SOTR before and 6 months after transplantation. A total of 798
SOTR, 130 of them vaccinated within 6 months of transplantation and 668 of them vaccinated more than 6 months since transplantation.
Seroprotection was similar in both groups: 73.1% vs. 76.5% for A/(H1N1)pdm (p 0.49), 67.5% vs. 74.1% for A/H3N2 (p 0.17) and 84.2%
vs. 85.2% for inﬂuenza B (p 0.80), respectively. Geometric mean titres after vaccination did not differ among groups: 117.32 (95%
conﬁdence interval (CI) 81.52, 168.83) vs. 87.43 (95% CI 72.87, 104.91) for A/(H1N1)pdm, 120.45 (95% CI 82.17, 176.57) vs. 97.86
(95% CI 81.34, 117.44) for A/H3N2 and 143.32 (95% CI 103.46, 198.53) vs. 145.54 (95% CI 122.35, 174.24) for inﬂuenza B, respectively.
After adjusting for confounding factors, time since transplantation was not associated with response to vaccination. No cases of rejection
or severe adverse events were detected in patients vaccinated within the ﬁrst 6 months after transplantation. In conclusion, inﬂuenza
vaccination within the ﬁrst 6 months after transplantation is as safe and immunogenic as vaccination thereafter. Thus, administration of
the inﬂuenza vaccine can be recommended as soon as 1 month after transplantation.
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rights reserved.
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p://dx.doi.org/10.1016/j.cmi.2015.07.014IntroductionAfter the 2009 inﬂuenza pandemic, substantial morbidity and
mortality due to inﬂuenza infection was described in solid organ
transplant recipients (SOTR) [1]. Given the risk of severe dis-
ease in this population, recommendations for diagnosis, pre-
vention and therapy of inﬂuenza infection were given by several
scientiﬁc societies [2–4].ious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Pérez-Romero et al. Inﬂuenza vaccination after organ transplantation 1040.e12Time since transplantation has been associated with a higher
risk of complications due to inﬂuenza infection in transplant
recipients. Patients diagnosed with inﬂuenza infection within the
ﬁrst 3 months after receiving a transplant have a ﬁve times
greater risk of developing severe disease compared to those
infected after the ﬁrst 3 months after transplantation [5].
Current recommendations, mostly based on expert opinion,
support inﬂuenza vaccination after 3 months after trans-
plantation [6,7]. More recent recommendations state that not
vaccinating may leave a transplant recipient vulnerable to
inﬂuenza infection for an entire inﬂuenza season. However,
results of immunologic response to inﬂuenza vaccination during
the ﬁrst 6 months after transplantation are controversial [2,8].
While some authors reported a lower response [6,9], others
found a similar response independent of the time since trans-
plantation [10]. In addition, most of the studies with patients
vaccinated within the ﬁrst 6 months after transplantation are
small series.
Although no solid evidence exists indicating that vaccination
can cause acute rejection, there has been worry that nonspe-
ciﬁc immune activation caused by vaccination could result in
transplant rejection. In this context, safety should be the pri-
mary consideration when administering the inﬂuenza vaccine
early after transplantation. Despite the need for preventing
inﬂuenza infection in the ﬁrst 6 months after transplantation,
solid evidence regarding the efﬁcacy and safety of inﬂuenza
vaccination is lacking. Further, adequately sized studies are
needed to clarify and ﬁrmly establish recommendations
regarding the optimal timing of inﬂuenza vaccination in the
transplant setting.
We hypothesized that early vaccination of SOTR had similar
immunologic responses to SOTR vaccinated 6 months after
transplantation. Thus, the aim of the study was to assess the
immunogenicity, efﬁcacy and safety of inﬂuenza vaccination in
SOTR before and after 6 months since transplantation.Material and MethodsSubjects and study design
We performed a multicentre prospective cohort study of
inﬂuenza vaccinated SOTR during four consecutive inﬂuenza
seasons. Kidney, heart and liver recipients older than 15 years
of age who received one dose of the inﬂuenza vaccine between
November 2009 and January 2013 were enrolled in 12 Spanish
university hospitals belonging to the Spanish Network for
Research in Infectious Diseases (REIPI). Patients were excluded
if they received the transplant less than 1 month before im-
munization, if they had an allergy to any of the vaccine com-
ponents or if they were pregnant. Serum samples wereClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infecticollected from each patient at the time of vaccination (baseline)
and 5 weeks after vaccination. Patients were followed up during
90 days and up to 10 months if inﬂuenza infection or adverse
effects were detected to evaluate the clinical efﬁcacy of the
vaccine. The study procedures were approved by the Univer-
sity Hospital Ethic Committee for Clinical Research according
with the Helsinki Declaration of the World Medical Associa-
tion. All patients provided written informed consent.
Clinical parameters and deﬁnitions
Baseline characteristics, immunologic and clinical response and
adverse effects, including graft rejection and mortality, were
recorded using a standardized questionnaire. Biopsies and his-
tologic evaluation of graft rejection were only performed in
cases of suspicion if signs of biochemical, echocardiographic or
spirometry testing disorders were detected. Comorbidities
were assessed by the Charlson comorbidity index [11].
Rejection was deﬁned by the Banff and International Society
for Heart and Lung Transplantation criteria [12]. Chronic renal
insufﬁciency was deﬁned as an estimated glomerular ﬁltration
rate of <60 mL/min/1.73 m2 for more than 3 months (modiﬁed
criteria of the Kidney Disease Improving Global Outcomes)
[13]. The deﬁnition of chronic liver disease was that of the
Charlson comorbidity index [11]. Induction therapy was
considered when administered within the 6 months before
vaccination. Hypogammaglobulinemia was deﬁned as IgG levels
lower than 700 mg/dL. The general immunosuppressive regi-
mens consisted of mycophenolate mofetil, calcineurin inhibitor
and prednisone. Heart and kidney transplant recipients with
medium-high immunologic risk for graft rejection or delayed
introduction of tacrolimus received induction therapy with
anti– interleukin 2 receptor monoclonal antibodies or poly-
clonal anti-thymocyte globulin. For liver transplant patients
where induction therapy was indicated, anti– interleukin 2 re-
ceptor monoclonal antibody therapy was used.
Vaccines
Patients from the 2009–2010 inﬂuenza season received the
pandemic H1N1-2009 (A/California/7/2009-H1N1) mono-
valent MF59-adjuvanted vaccine (Focetria, Novartis, Siena,
Italy). Patients from the 2010–2011 and 2011–2012 inﬂuenza
seasons received the trivalent nonadjuvant inactivated vaccine
(Gripavac, Sanoﬁ-Pasteur MSD, Madrid, Spain) containing the
following strains: A/California/7/2009-H1N1, A/Perth/16/2009-
H3N2 and B/Brisbane/60/2008. Patients from the 2012–2013
inﬂuenza season received one dose of the trivalent nonadjuvant
inactivated vaccine (Mutagrip, Sanoﬁ-Pasteur MSD) with the
following strains: A/California/7/2009-H1N1, A/Victoria/361/
2011-H3N2 and B/Wisconsin/1/2010. Adverse events were
assessed according to established criteria [14].ous Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1040.e11–1040.e18
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Microneutralization assays were performed as previously
described [1,15] with some modiﬁcations (Supplementary
Materials). The average absorbance (A450) from the quadru-
plicate wells of virus-infected (VC) and uninfected (CC) control
wells was determined, and the neutralizing endpoint was
determined by using a 50% speciﬁc signal calculation. The end
point titre was expressed as the reciprocal of the highest
dilution of serum with an A450 value less than x, where
x = [(average A450 of VC wells) − (average A450 of CC wells)]/
2. Sera were considered positive if titres were 40 obtained in
at least two independent assays. Vaccination efﬁcacy parame-
ters were as follows: geometric mean titre (GMT), deﬁned as
mean antibody titre in the group of vaccinated individuals;
seroprotection rate as percentage of subjects with antibody
titre 1:40; seroconversion rate as percentage of subjects with
a fourfold increase in antibody titres from baseline; and geo-
metric mean ratio, deﬁned as seroconversion factor after
vaccination to before vaccination.
Statistical analysis
Patients were grouped by timing of inﬂuenza vaccination after
transplantation into two groups, early and late. Patients in the
early group received the inﬂuenza vaccine less than 6 months
after transplantation, and patients in the late group received the
inﬂuenza vaccine more than 6 months after transplantation. A
descriptive statistical analysis was performed. Continuous var-
iables were expressed as median and interquartile range or
mean ± standard deviation if adjusted to normal distribution,
and evaluated by Shapiro-Wilk or Kolmogorov-Smirnov tests
when appropriate. The main primary outcome for the analysis
was seroprotection. Secondary outcomes were seroconver-
sion, GMT after vaccination, safety and clinical effectiveness.
For bivariate analysis, the chi-square test, Fisher’s exact test or
the McNemar test were used for categorical variables, and
Bonferroni correction was applied when appropriate. For
quantitative variables, the Mann-Whitney test or Student’s t test
were used. If the variance was not homogeneous (Levene test),
the Welch test was applied (ANOVA). For multivariate analysis,
mixed-effects regression models were performed to control
the effect of time since transplantation with possible con-
founding variables. Factors associated in the bivariate analysis
and those considered clinically relevant were included in the
models. For immunogenicity analysis, the geometric mean
antibody titres at each time point were used. Relative risk and
95% conﬁdence interval (CI) were calculated by taking the
exponent of natural logarithm of the mean and 95% CI. Results
were analyzed by PASW Statistic 18.0.1 software. Statistical
signiﬁcance was established as a p value of <0.05. All reported p
values were based on two-tailed tests.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectiResultsPatient characteristics
A total of 798 SOTR (38.8% liver, 41.7% kidney, 19.4% heart)
were included in the study. The early vaccination group was
composed of 130 patients (16.2%) (median time to vaccination,
4.7 months, interquartile range 3.5–5.7 months) and 668 SOTR
(83.8%) were in the late vaccination group (median time to
vaccination, 44.5, months, interquartile range 18.4–96.1
months). Patients were more frequently men (69.8%), and the
median age was 56 years (interquartile range 47.0–63.0 years).
The type of transplant was liver in 333 cases (41.7%), kidney in
310 (38.8%) and heart in 155 (19.4%). Comorbidities appeared
in 80.5% of cases, with diabetes mellitus and chronic heart
disease being the most frequent (Table 1).
Baseline antibody titres
At baseline, 393 patients (49.2%) had preexisting antibody titres
for A/(H1N1)pdm, 345 (70.3%) for inﬂuenza A/H3N2 and 392
(79.8%) for inﬂuenza B. Prevaccination antibody titres and GMT
were signiﬁcantly higher in the early vaccination group for
inﬂuenza A/(H1N1)pdm and inﬂuenza B (Table 2).
Immunologic response to vaccination
Overall, there were no signiﬁcant differences in the rate of sero-
protectionbetweenpatients in the earlyor late vaccination groups.
The respective seroprotection rates for inﬂuenza A/(H1N1)pdm
were 73.1% vs. 76.5% (p 0.49), 67.5% vs. 74.1% for inﬂuenza A/
H3N2 (p 0.17) and 84.2% vs. 85.2% for inﬂuenza B (p 0.80). After
vaccination, the proportion of seroprotected patients before and
after vaccination changed signiﬁcantly (p < 0.001) in both cohorts
for the three viruses studied (Supplementary Table 1).
GMT after transplantation was similar (p > 0.05) for the early
and late vaccination groups, respectively, as follows: 117.32
(81.52–168.83) vs. 87.43 (72.87–104.91) for inﬂuenza A/
(H1N1)pdm, 120.45 (82.17–176.57) vs. 97.86 (81.34–117.44)
for inﬂuenza A/H3N2 and 143.32 (103.46–198.53) vs. 145.54
(122.35–174.24) (Table 2).
Immunologic response to vaccination was also analyzed
excluding patients with seroprotection at baseline. In these
patients, the seroconversion rates in the early and late vacci-
nation groups were, respectively, as follows: 61.1% and 71.6%
(p 0.048) for A/(H1N1)pdm, 46.4% and 57.9% (p 0.18) for A/
H3N2 and 85.7% and 78.0% (p 0.26) for inﬂuenza B.
No differences were observed when we analyzed the im-
mune response according to transplanted organ
(Supplementary Table 2).
In the early vaccination group of 130 SOTR, the seropro-
tection ratewas similar among patients stratiﬁed according to theous Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1040.e11–1040.e18
TABLE 1. Characteristics, comorbidities and background of solid organ transplant recipients receiving inﬂuenza vaccinations
between 2009 and 2013
Variable
Total
(n [ 798)
Early group
(n [ 130)
Late group
(n [ 668)
RR (95% CI)/β
coefﬁcient (95% CI)
Cohort
2009–2010 284 (35.5) 14 (10.7) 270 (40.4) 0.26 (0.16, 0.44)
2010–2011 95 (11.9) 10 (7.6) 85 (12.7) 0.60 (0.32, 1.13)
2011–2012 88 (11.0) 24 (18.4) 64 (9.5) 1.92 (1.25, 2.96)
2012–2013 331 (41.4) 82 (63.0) 249 (37.2) 1.35 (1.48, 1.64)
Male sex 557 (69.8) 94 (72.3) 463 (69.3) 0.80 (0.65, 0.98)
Age (years), median (range) 56.0 (47.0–63.0) 54.0 (44.0–62.0) 56.0 (47.0–56.0) −0.001 (−0.003, 0.001)
Type of transplant
Kidney 310 (38.8) 45 (34.6) 265 (39.7) 1.4 (1.12, 1.73)
Liver 333 (41.7) 77 (59.2) 256 (38.3) 1.54 (1.30, 1.83)
Heart 155 (19.4) 8 (6.2) 147 (22.0) 0.19 (0.09, 0.38)
Immunosuppressive therapy
Tacrolimus 559 (70.1) 113 (86.9) 446 (66.8) 2.08 (1.89, 2.29)
Mycophenolate mofetil 605 (75.8) 101 (77.6) 504 (75.6) 1.06 (0.95, 1.17)
Cyclosporine 159 (19.9) 10 (7.7) 149 (22.3) 0.34 (0.18, 0.63)
mTOR inhibitors 106 (13.3) 7 (5.4) 99 (14.8) 0.36 (0.17, 0.76)
Antibody induction 63 (7.8) 37 (29.1) 26 (3.9) 7.31 (4.59, 11.6)
Comorbidity
Chronic liver disease 91 (11.4) 10 (7.7) 81 (12.1) 0.63 (0.33, 1.19)
Diabetes mellitus 196 (24.5) 22 (16.9) 176 (26.3) 0.64 (0.43, 0.95)
Chronic heart disease 162 (20.3) 27 (20.8) 135 (20.2) 1.02 (0.71, 1.48)
Chronic kidney disease 150 (18.8) 14 (10.8) 136 (20.4) 0.52 (0.31, 0.88)
Hypogammaglobulinemia 131 (16.4) 35 (29.2) 96 (16.5) 1.87 (1.33, 2.62)
Previous season inﬂuenza vaccination 539 (67.5) 83 (63.6) 456 (69.5) 0.93 (0.81, 1.07)
Cohort 2009–2010 166 (58.4) 5 (35.7) 161 (59.6) 1.07 (0.72, 1.61)
Cohort 2010–2011 70 (73.6) 6 (60.0) 64 (75.3) 0.79 (0.47, 1.34)
Cohort 2011–2012 79 (89.7) 19 (79.2) 60 (93.8) 0.84 (0.68, 1.04)
Cohort 2012–2013 223 (67.3) 52 (64.2) 171 (72.2) 0.88 (0.74, 1.06)
Data are presented as n (%) unless otherwise indicated. Parameters were compared by multiple comparison chi-square test or linear regression.
CI, conﬁdence interval; RR, relative risk.
CMI Pérez-Romero et al. Inﬂuenza vaccination after organ transplantation 1040.e14months elapsed since transplantation (Supplementary Table 3).
Of them, 21 patients (16.1%) were vaccinated within the ﬁrst 3
months after receiving the transplant, with postvaccination
seroprotection rates of 80.0% for inﬂuenza A/(H1N1)pdm,
76.1% for inﬂuenza A/H3N2 and 76.1% for inﬂuenza B, and with
seroconversion rates of 71.4% for inﬂuenza A/(H1N1)pdm,TABLE 2. Antibody response against inﬂuenza A/(H1N1)pdm, A
vaccination
Variable Early group Late gr
Baseline seroprotection rate, n (%)
A/(H1N1)pdm 60 (46.2) 226 (
A/H3N2 51 (44.7) 166 (
B 78 (68.4) 182 (
Postvaccine seroprotection rate, n (%)
A/(H1N1)pdm 95 (73.1) 507 (
A/H3N2 77 (67.5) 277 (
B 96 (84.2) 299 (
Seroconversion rate, n (%)
A/(H1N1)pdm 68 (52.3) 379 (
A/H3N2 53 (46.5) 175 (
B 45 (39.5) 179 (
GMT (95% CI)
A/(H1N1)pdm
Baseline 32.59 (23.59, 45.03) 31.93 (
After vaccination 117.32 (81.52, 168.83) 87.43 (
A/H3N2 (95% CI)
Baseline 34.59 (24.01, 49.82) 27.33 (
After vaccination 120.45 (82.17, 176.57) 97.86 (
B (95% CI)
Baseline 54.19 (40.62, 72.28) 34.94 (
After vaccination 143.32 (103.46, 198.53) 145.54 (
GMR (95% CI)
A/(H1N1)pdm 3.59 (2.47, 5.23) 2.73 (
A/H3N2 3.48 (2.50, 4.84) 3.58 (
B 2.64 (1.82, 3.83) 4.16 (
Parameters were compared by multiple comparison chi-square test or linear regression.
CI, conﬁdence interval; GMT, geometric mean titre; GMR, geometric mean ratio; RR, relati
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infecti47.6% for inﬂuenza A/H3N2 and 42.8% for inﬂuenza B. These
parameters were not different from those vaccinated afterward.
Time since transplantation to vaccination (early vs. late),
when controlled for other possible confounding factors, did not
contribute to explain the variability of the seroprotection after
vaccination or the GMT after vaccination for all virus types/H3N2 and B virus according to time from transplant to
oup p
RR (95% CI)/β
coefﬁcient (95% CI)
33.8) 0.007 1.36 (1.10, 1.68)
44.5) 0.947 1.15 (0.89, 1.47)
52.0) 0.002 1.53 (1.27, 1.83)
76.5) 0.494 0.96 (0.86, 1.07)
74.1) 0.172 0.99 (0.84, 1.16)
85.2) 0.800 1.14 (1.01, 1.29)
56.7) 0.352 0.92 (0.77, 1.10)
46.9) 0.936 1.13 (0.89.1.44)
51.1) 0.030 0.89 (0.69, 1.16)
26.33, 38.73) 0.000 0.02 (0.01, 0.04)
72.87, 104.91) 0.287 0.008 (−0.007, 0.02)
22.92, 32.59) 0.109 0.01 (−0.004, 0.03)
81.34, 117.44) 0.140 0.01 (−0.005, 0.030)
29.54, 39.80) 0.002 0.03 (0.01, 0.06)
122.35, 174.24) 0.741 0.004 (−0.01, 0.02)
2.23, 3.35) 0.051 −0.01 (−0.02, 0.00)
2.90, 4.14) 0.921 −0.001 (−0.02, 0.01)
3.39, 5.10) 0.039 −0.02 (−0.04, −0.001)
ve risk.
ous Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1040.e11–1040.e18
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presence of baseline antibody titres was associated with higher
rates of seroprotection for all three types of inﬂuenza viruses:
79.8% vs. 71.6% for inﬂuenza A/(H1N1)pdm (p 0.01), 79.9% vs.
55.2% for inﬂuenza A/H3N2 (p < 0.001) and 89.3% vs. 67.7%
for inﬂuenza B (p < 0.001), as well as higher posttransplant
GMT: 134.03 vs. 83.71 for inﬂuenza A/(H1N1)pdm (p < 0.001),
126.03 vs. 53.65 for inﬂuenza A/H3N2 (p < 0.001) and 164.37
vs. 99.34 for inﬂuenza B (p 0.002; Tables 3–5).
Kidney transplant recipients had lower seroprotection rates
compared to liver transplant recipients to inﬂuenza A/(H1N1)
pdm (odds ratio (OR) 0.60, 95% CI 0.38, 0.94) and inﬂuenza A/
H3N2 (OR 0.34 95% CI 0.19, 0.62). Patients with heart
transplants had a lower seroprotection rate for inﬂuenza A/
H3N2 (OR 0.37 95% CI 0.17, 0.79) and inﬂuenza B (OR 0.28
95% CI 0.11, 0.68) compared to liver transplant recipients
(Tables 3–5).
Clinical failure to inﬂuenza vaccine
Nine patients (1.1%) were diagnosed with inﬂuenza disease a
median of 35 days after vaccination (range 8–73 days), and 5
(55%) were admitted to hospital. Eight patients were in the late
vaccination group (88.8%) and one in the early vaccination
group (p 0.1). All patients had mild symptoms, and none
developed graft rejection, died or required intensive care
(Supplementary Table 4).
Vaccination safety
One kidney recipient vaccinated 118 months after trans-
plantation (inﬂuenza season 2012–2013) was diagnosed with
chronic graft rejection 83 days after receipt of the transplant.
The decrease in creatinine clearance started before vaccinationTABLE 3. Mixed-effects regression model of factors inﬂuencing
A(H1N1)pdm grouped by time since transplantationa
Variable
Postvaccine seroprotectionb
OR (95% CI)
Age (years) 0.99 (0.98, 1.01)
Male (yes vs. no) 0.99 (0.67, 1.46)
Type of transplant
Liver Reference
Kidney 0.60 (0.38, 0.94)
Heart 0.76 (0.42, 1.38)
Use of mTOR (yes vs. no) 1.37 (0.75, 2.51)
Diabetes (yes vs. no) 1.11 (0.71, 1.73)
Hypogammaglobulinemia (yes vs. no) 0.72 (0.46, 1.12)
Chronic kidney disease (yes vs. no) 0.98 (0.62, 1.55)
Chronic liver disease (yes vs. no) 0.80 (0.44, 1.46)
Previous season vaccine (yes vs. no) 0.98 (0.65, 1.48)
Baseline antibody titre (yes vs. no) 1.68 (1.15, 2.45)
CI, conﬁdence interval; GMT, geometric mean titre; mTOR, mammalian target of rapamycin
aGroup variable: time since transplant 2 to 6 months. Standard deviation: b1.59 × 10−10 and
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectiand was chronologically related to the onset of rifampicin
therapy administered to treat miliary tuberculosis.
No other adverse events were detected in patients in the
early or late vaccination groups.DiscussionThe present study shows that inﬂuenza vaccination of SOTR is
safe and effective after the ﬁrst month after transplantation,
with a rate of seroprotection and GMT similar to that obtained
in patients vaccinated after 6 months since transplantation.
The response to inﬂuenza vaccination in the transplant
population ranges from 15% to 90% [1,10,15–24]. Factors such
as lung transplant [18,25] and use of immunosuppressants
(mycophenolate mofetil or mTOR (mammalian target of rapa-
mycin) inhibitors) [1,6,16] have been related to decreased
antibody response. However, it remains unresolved whether
the strong immunosuppressive regimens provided in the ﬁrst
months after transplantation affect the response to inﬂuenza
vaccine. While Lawal et al. [9] described that only 1 (14%) of 7
patients receiving the inﬂuenza vaccine within 4 months after
liver transplantation responded to vaccination, Birdwell et al.
[10] concluded that the protection achieved was similar be-
tween the 19 kidney transplant recipients who received the
vaccine less that 6 months after transplantation compared to
the 34 patients vaccinated more than 6 months after trans-
plantation. A recent randomized study, comparing intradermal
versus intramuscular inﬂuenza vaccination in a cohort of 212
SOTR, found an association in the univariate but not in the
multivariate analysis between receiving the vaccine before 6
months since transplantation with a poor vaccine response [6].postvaccine seroprotection and GMT response to inﬂuenza
Postvaccine GMTc
p β1 coefﬁcient (95% CI) p
0.43 0.001 (−0.009, 0.012) 0.81
0.94 0.19 (−0.09, 0.47) 0.19
Reference
0.03 −0.43 (−0.74, −0.12) 0.006
0.37 −0.37 (−0.76, 0.04) 0.07
0.31 0.05 (−0.35, 0.44) 0.82
0.66 −0.07 (−0.39, 0.24) 0.64
0.15 −0.32 (−0.65, 0.01) 0.06
0.95 0.02 (−0.31, 0.34) 0.91
0.47 −0.09 (−0.52, 0.33) 0.67
0.94 −0.10 (−0.39, 0.19) 0.51
0.01 0.55 (0.29, 0.81) <0.001
; OR, odds ratio.
c 2.73 × 10−10.
ous Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1040.e11–1040.e18
TABLE 4. Mixed-effects regression model of factors inﬂuencing postvaccine seroprotection and GMT response to inﬂuenza
A/H3N2 grouped by time since transplantationa
Variable
Postvaccine seroprotectionb Postvaccine GMTc
OR (95% CI) p β1 coefﬁcient (95% CI) p
Age 0.98 (0.96, 1) 0.08 −0.01 (−0.03, 0.004) 0.17
Male (yes vs. no) 1.21 (0.73, 2.01) 0.46 0.14 (−0.22, 0.5) 0.45
Type of transplant
Liver Reference Reference
Kidney 0.34 (0.19, 0.62) <0.001 −0.61 (−1.01, −0.21) 0.003
Heart 0.37 (0.17, 0.79) 0.01 −0.59 (−1.15, −0.04) 0.04
Use of mTOR (yes vs. no) 1.48 (0.66, 3.34) 0.34 0.09 (−0.46, 0.64) 0.74
Diabetes (yes vs. no) 0.98 (0.55, 1.73) 0.95 −0.13 (−0.53, 0.27) 0.53
Hypogammaglobulinemia (yes vs. no) 0.92 (0.54, 1.58) 0.780 −0.22 (−0.63, 0.19) 0.294
Chronic kidney disease (yes vs. no) 1.44 (0.74, 2.8) 0.29 0.37 (−0.1, 0.83) 0.12
Chronic liver disease (yes vs. no) 1.68 (0.74, 3.8) 0.21 0.53 (0.01, 1.05) 0.05
Previous season vaccine (yes vs. no) 1.24 (0.71, 2.15) 0.45 0.03 (−0.38, 0.44) 0.88
Baseline antibody titre (yes vs. no) 4.22 (2.56, 6.95) <0.001 0.97 (0.6, 1.34) <0.001
CI, conﬁdence interval; GMT, geometric mean titre; mTOR, mammalian target of rapamycin; OR, odds ratio.
aGroup variable: time since transplant 2 to 6 months. Standard deviation: b2.89 × 10−10 and c2.10 × 10−10.
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from transplantation was not speciﬁed.
It is crucial to deﬁne the correct time for inﬂuenza vacci-
nation in transplant recipients. Thus, a delay in vaccination after
transplantation may lead to vulnerability of transplant recipients
to inﬂuenza infection, a period during which recipients are
especially susceptible to inﬂuenza-related complications. As
previously mentioned, little evidence is available regarding the
immunogenicity of inﬂuenza vaccination within the ﬁrst months
after solid organ transplantation [2,4,5,9,10].
To our knowledge, the results presented here represent the
largest cohort of SOTR receiving inﬂuenza vaccination within
the ﬁrst 6 months after receiving a transplant. We found that
receiving the vaccine within 6 months after transplantation was
not associated with a poor vaccine response when controllingTABLE 5. Mixed-effects regression model of factors inﬂuencing p
grouped by time since transplantationa
Variable
Postvaccine seroprotectionb
OR (95% CI)
Age 0.98 (0.96, 1.01)
Male (yes vs. no) 0.95 (0.50, 1.79)
Type of transplant
Liver Reference
Kidney 0.59 (0.28, 1.26)
Heart 0.28 (0.11, 0.68)
Use of mTOR (yes vs. no) 1.23 (0.47, 3.19)
Diabetes (yes vs. no) 1.22 (0.57, 2.61)
Hypogammaglobulinemia (yes vs. no) 1.12 (0.53, 2.39)
Chronic kidney disease (yes vs. no) 1.48 (0.64, 3.41)
Chronic liver disease (yes vs. no) 1.22 (0.47, 3.13)
Previous season vaccine (yes vs. no) 0.60 (0.27, 1.30)
Antibodies titre baseline (yes vs. no) 5.46 (2.82, 10.55)
CI, conﬁdence interval; GMT, geometric mean titre; mTOR, mammalian target of rapamycin
aGroup variable: time since transplant 2 to 6 months. Standard deviation: b0.198 × 10−10 and
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectifor other possible confounding variables. The same ﬁndings
were observed when only patients vaccinated during the ﬁrst 3
months receiving a transplant were considered.
Nonseroprotected patients at baseline in the early post-
transplantation group had a seroconversion rate that did not
differ from those vaccinated thereafter. Previous results sug-
gested that having baseline seroprotection promoted signiﬁ-
cantly higher GMT after vaccination compared to patients
without baseline titres [15]. Patients vaccinated within the ﬁrst
6 months after transplantation had signiﬁcantly higher baseline
titres for inﬂuenza A/(H1N1)pdm and inﬂuenza B, probably as a
result of the remaining long-term inﬂuenza antibodies from the
previous year’s inﬂuenza vaccination. This ﬁnding, which to our
knowledge has not been previously described, highlights the
importance of vaccinating patients on transplant waiting lists orostvaccine seroprotection and GMT response to inﬂuenza B
Postvaccine GMTc
p β1 coefﬁcient (95% CI) p
0.2 −0.02 (−0.03, −0.01) 0.004
0.86 0.06 (−0.28, 0.40) 0.73
Reference
0.18 −0.73 (−1.10, −0.35) <0.001
0.005 −1.02 (−1.56, −0.48) <0.001
0.67 0.11 (−0.41, 0.63) 0.67
0.61 0.05 (−0.33, 0.44) 0.79
0.76 −0.04 (−0.44, 0.36) 0.84
0.36 0.24 (−0.19, 0.67) 0.27
0.68 0.15 (−0.34, 0.64) 0.54
0.2 −0.06 (−0.43, 0.31) 0.75
<0.001 0.61 (0.22, 0.99) 0.002
; OR, odds ratio.
c6.24 × 10−11.
ous Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1040.e11–1040.e18
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against inﬂuenza infection after transplantation.
The response to inﬂuenza vaccination had also been related
to the type of virus included in the formulation, showing lower
responses to inﬂuenza B [26] and responses that varied from
25.3% to 92.7% to different subtypes of inﬂuenza A virus
[16,26,27]. In the present study, although there were some mild
differences, overall, the response was similar within both co-
horts for the three inﬂuenza strains across different inﬂuenza
seasons.
A controversy concerning the risk of allograft rejection
triggered by the immune response against the inﬂuenza vaccine
has been raised in this population, with the rationale being that
while the immunosuppression may diminish the immunoge-
nicity of vaccination, inﬂuenza vaccination may stimulate a T cell
response leading to organ rejection, which might be especially
relevant in the early stages after receiving a transplant [28].
Previous studies involving SOTR receiving seasonal inﬂuenza
vaccine did not found this relationship [16,19,28]. In our
cohort, one patient (in the late vaccination group) experienced
graft rejection after inﬂuenza vaccination. However, this patient
had other possible causes of rejection, such as low immuno-
suppressive drug levels. In addition, episodes of acute allograft
rejection and permanent graft dysfunction have also been
related to seasonal and pandemic inﬂuenza virus infection
[5,29,30].
Some limitations of the study need to be mentioned. First,
some episodes of asymptomatic rejection might have not been
diagnosed because routine biopsies were not performed.
However, during patient follow-up, complications, including
clinical evidence of rejection, were not detected. Second,
asymptomatic inﬂuenza infection might have not been diag-
nosed. However, the extent to which these nonsymptomatic
episodes may be related to the administration of the vaccine it
is unknown. Third, although the number of patients who
received the vaccine during the ﬁrst 3 months might seem
small, this is the largest reported series of patients vaccinated
within the ﬁrst 3 months of transplantation. Fourth, because
only few patients received lymphocyte-depleting antibodies or
rituximab therapy, our results may not be applicable to patients
with this immunosuppression regimen. Finally, although the
number of heart recipients vaccinated in the early vaccination
group was small, inﬂuenza vaccine was safe for all patients, and
the rate of seroprotection was above 67% for all inﬂuenza
strains.
In summary, the results of the present study show that
inﬂuenza vaccination is as safe and immunogenic in patients
within the ﬁrst 6 months after kidney and liver transplantation
as in those vaccinated after 6 months since transplantation.
Given the immunologic response, the lack of severe adverseClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectievents and the high rate of complications of inﬂuenza infection
in the early posttransplantation period, administration of the
inﬂuenza vaccine can be recommended as soon as 1 month
after transplantation. In addition, compliance of pre-
transplantation annual seasonal inﬂuenza vaccination in patients
with end-organ disease should be pursued in order to promote
better inﬂuenza immunologic protection early after
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